Therefore, researchers need to pay more attention to the interaction mechanism of these HBx-TGF-β axis, and develop anti-tumor drugs that can target the common pathway of this axis, bringing new hope to the drug treatment of hepatocellular carcinoma. Here, TGFB1 is linked to neoplasm.